IVI gets $15.7 million to conduct P3 trials for Vi-DT typhoid conjugate vaccine

Posted on by
  • The International Vaccine Institute (IVI) said it has received a $15.7 million grant from the Bill & Melinda Gates Foundation to develop a typhoid conjugate vaccine for public sector markets.
  • The grant will fund the phase 3 clinical trials of the Vi-DT typhoid conjugate vaccine (TCV) to take place in Nepal and the Philippines over the next two years.
  • IVI Director General Jerome Kim also said, “With the launch of Phase 3 clinical trials, we have reached the final milestone in our quest to develop an innovative typhoid vaccine that should be safe and effective for children six months and older.”